Yash R Somnay1, Eric Weinlander1, Amal Alfhefdi1, David Schneider1, Rebecca S Sippel1, Herbert Chen2. 1. Section of Endocrine Surgery, Division of General Surgery, Department of Surgery, University of Wisconsin, Madison, Wisconsin. 2. Section of Endocrine Surgery, Division of General Surgery, Department of Surgery, University of Wisconsin, Madison, Wisconsin. Electronic address: chen@surgery.wisc.edu.
Abstract
BACKGROUND: Tertiary hyperparathyroidism (3HPT) is defined as the persistent hyperproduction of parathyroid hormone and resulting hypercalcemia after renal transplantation. Here, we examine the utility of radioguided parathyroidectomy (RGP) in patients with 3HPT. MATERIALS AND METHODS: We reviewed a prospective surgery database containing 80 3HPT patients who underwent RGP from January 2001-July 2014 at our institution. We evaluated patient demographics, operative management, radioguided neoprobe utilization, and operative outcomes. Data are reported as mean ± standard error of the mean. RESULTS: The mean age of the patients was 52 ± 1 y, and 46% were male. A total of 69 patients had hyperplasia and received subtotal parathyroidectomy, whereas 5 patients had double adenomas and 6 patients had single adenomas. The average calcium level among 3HPT patients was 10.8 ± 0.1 mg/dL preoperatively and 8.7 ± 0.1 mg/dL postoperatively. In vivo radioguided counts normalized to background counts averaged 145 ± 4%, whereas ex vivo counts normalized to background counts averaged 69 ± 5%. All but one ex vivo count was >20%. Ectopically located glands were successfully localized in 38 patients using the gamma probe. Ex vivo percentage did not correlate with parathyroid gland weight, preoperative parathyroid hormone, or preoperative calcium. Our radioguided approach achieved normocalcemia in 96% of 3HPT patients undergoing RGP; two patients developed recurrent disease. CONCLUSIONS: In this series, all enlarged parathyroid glands were localized and resected using the gamma probe. Thus, RGP reliably localizes adenomatous, hyperplastic, and ectopically located glands in patients with 3HPT, resulting in high cure rate after resection.
BACKGROUND:Tertiary hyperparathyroidism (3HPT) is defined as the persistent hyperproduction of parathyroid hormone and resulting hypercalcemia after renal transplantation. Here, we examine the utility of radioguided parathyroidectomy (RGP) in patients with 3HPT. MATERIALS AND METHODS: We reviewed a prospective surgery database containing 80 3HPTpatients who underwent RGP from January 2001-July 2014 at our institution. We evaluated patient demographics, operative management, radioguided neoprobe utilization, and operative outcomes. Data are reported as mean ± standard error of the mean. RESULTS: The mean age of the patients was 52 ± 1 y, and 46% were male. A total of 69 patients had hyperplasia and received subtotal parathyroidectomy, whereas 5 patients had double adenomas and 6 patients had single adenomas. The average calcium level among 3HPTpatients was 10.8 ± 0.1 mg/dL preoperatively and 8.7 ± 0.1 mg/dL postoperatively. In vivo radioguided counts normalized to background counts averaged 145 ± 4%, whereas ex vivo counts normalized to background counts averaged 69 ± 5%. All but one ex vivo count was >20%. Ectopically located glands were successfully localized in 38 patients using the gamma probe. Ex vivo percentage did not correlate with parathyroid gland weight, preoperative parathyroid hormone, or preoperative calcium. Our radioguided approach achieved normocalcemia in 96% of 3HPTpatients undergoing RGP; two patients developed recurrent disease. CONCLUSIONS: In this series, all enlarged parathyroid glands were localized and resected using the gamma probe. Thus, RGP reliably localizes adenomatous, hyperplastic, and ectopically located glands in patients with 3HPT, resulting in high cure rate after resection.
Authors: A M D'Alessandro; J S Melzer; J D Pirsch; H W Sollinger; M Kalayoglu; W B Vernon; F O Belzer; J R Starling Journal: Surgery Date: 1989-12 Impact factor: 3.982
Authors: W Jalloul; R Tibu; T M Ionescu; C R Stolniceanu; I Grierosu; A Tarca; L Ionescu; M C Ungureanu; D Ciobanu; V Ghizdovat; C Stefanescu Journal: Acta Endocrinol (Buchar) Date: 2021 Jul-Sep Impact factor: 0.877